The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study

Daniel A Rossignol, Lanier W Rossignol, S Jill James, Stepan Melnyk, Elizabeth Mumper, Daniel A Rossignol, Lanier W Rossignol, S Jill James, Stepan Melnyk, Elizabeth Mumper

Abstract

Background: Recently, hyperbaric oxygen therapy (HBOT) has increased in popularity as a treatment for autism. Numerous studies document oxidative stress and inflammation in individuals with autism; both of these conditions have demonstrated improvement with HBOT, along with enhancement of neurological function and cognitive performance. In this study, children with autism were treated with HBOT at atmospheric pressures and oxygen concentrations in current use for this condition. Changes in markers of oxidative stress and inflammation were measured. The children were evaluated to determine clinical effects and safety.

Methods: Eighteen children with autism, ages 3-16 years, underwent 40 hyperbaric sessions of 45 minutes duration each at either 1.5 atmospheres (atm) and 100% oxygen, or at 1.3 atm and 24% oxygen. Measurements of C-reactive protein (CRP) and markers of oxidative stress, including plasma oxidized glutathione (GSSG), were assessed by fasting blood draws collected before and after the 40 treatments. Changes in clinical symptoms, as rated by parents, were also assessed. The children were closely monitored for potential adverse effects.

Results: At the endpoint of 40 hyperbaric sessions, neither group demonstrated statistically significant changes in mean plasma GSSG levels, indicating intracellular oxidative stress appears unaffected by either regimen. A trend towards improvement in mean CRP was present in both groups; the largest improvements were observed in children with initially higher elevations in CRP. When all 18 children were pooled, a significant improvement in CRP was found (p = 0.021). Pre- and post-parental observations indicated statistically significant improvements in both groups, including motivation, speech, and cognitive awareness (p < 0.05). No major adverse events were observed.

Conclusion: In this prospective pilot study of children with autism, HBOT at a maximum pressure of 1.5 atm with up to 100% oxygen was safe and well tolerated. HBOT did not appreciably worsen oxidative stress and significantly decreased inflammation as measured by CRP levels. Parental observations support anecdotal accounts of improvement in several domains of autism. However, since this was an open-label study, definitive statements regarding the efficacy of HBOT for the treatment of individuals with autism must await results from double-blind, controlled trials.

Trial registration: clinicaltrials.gov NCT00324909.

Figures

Figure 1
Figure 1
Changes in mean blood values before and after hyperbaric therapy at both 1.3 atm and 1.5 atm. The first column in a-d is the mean value for control children as described by James et al. [51] and is included as a standard reference (labeled as "control"). P-values and blood levels are listed above the bar graphs. a: Changes in mean oxidized glutathione levels. b: Changes in mean tGSH/GSSG.c: Changes in mean fGSH/GSSG. d: Changes in mean adenosine levels
Figure 2
Figure 2
Changes in mean CRP before and after hyperbaric therapy at both 1.3 atm and 1.5 atm. P-values and blood levels are listed above the bar graphs.
Figure 3
Figure 3
Changes in clinical scales at 1.3 atm and 24% oxygen. Declining scores on each scale indicate clinical improvements. Scores are listed above the bar graphs at baseline (0) and after every 10 treatments (10, 20,30, and 40). P-values are listed above the bar graphs. a:Changes in ABC-C subscales at 1.3 atm and 24% oxygen. b:Changes in SRS subscales at 1.3 atm and 24% oxygen. c: Changes in ATEC subscales at 1.3 atm and 24% oxygen.
Figure 4
Figure 4
Changes in clinical scales at 1.5 atm and 100% oxygen. Declining scores on each scale indicate clinical improvements. Scoresare listed above the bar graphs at baseline (0) and after every 10 treatments (10, 20, 30, and 40). P-values are listed above the bar graphs. a: Changes in ABC-C subscales at 1.5 atm and 100% oxygen. b: Changes in SRS subscales at 1.5 atm and 100% oxygen. c: Changes in ATEC subscales at 1.5 atm and 100% oxygen.

References

    1. CDC Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders – autism and developmental disabilities monitoring network, six cities, United States. 2000. MMWR. 2007;56:1–40.
    1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Press; 1994.
    1. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113:e472–486. doi: 10.1542/peds.113.5.e472.
    1. Charman T, Taylor E, Drew A, Cockerill H, Brown JA, Baird G. Outcome at 7 years of children diagnosed with autism at age 2: predictive validity of assessments conducted at 2 and 3 years of age and pattern of symptom change over time. J Child Psychol Psychiatry. 2005;46:500–513. doi: 10.1111/j.1469-7610.2004.00377.x.
    1. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A. Autism from 2 to 9 years of age. Arch Gen Psychiatry. 2006;63:694–701. doi: 10.1001/archpsyc.63.6.694.
    1. Baird G, Charman T, Baron-Cohen S, Cox A, Swettenham J, Wheelwright S, Drew A. A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2000;39:694–702. doi: 10.1097/00004583-200006000-00007.
    1. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108:1155–1161. doi: 10.1542/peds.108.5.1155.
    1. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093–3099. doi: 10.1001/jama.285.24.3093.
    1. Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901–909. doi: 10.1007/s10803-006-0131-0.
    1. Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67:216–228. doi: 10.1016/j.mehy.2006.02.009.
    1. Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses. 2007;68:1208–1227. doi: 10.1016/j.mehy.2006.09.064.
    1. Feldmeier JJ, Chairman and Editor . Hyperbaric oxygen 2003: indications and results: the hyperbaric oxygen therapy committee report. Kensington, MD: Undersea and Hyperbaric Medicine Society; 2003.
    1. Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ. 1998;317:1140–1143.
    1. Moss MC, Scholey AB, Wesnes K. Oxygen administration selectively enhances cognitive performance in healthy young adults: a placebo-controlled double-blind crossover study. Psychopharmacology (Berl) 1998;138:27–33. doi: 10.1007/s002130050641.
    1. Jacobs EA, Winter PM, Alvis HJ, Small SM. Hyperoxygenation effect on cognitive functioning in the aged. N Engl J Med. 1969;281:753–757.
    1. Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE. Results of a prospective randomized trial for treatment of severely brain-injured patients with hyperbaric oxygen. J Neurosurg. 1992;76:929–934.
    1. Golden ZL, Neubauer R, Golden CJ, Greene L, Marsh J, Mleko A. Improvement in cerebral metabolism in chronic brain injury after hyperbaric oxygen therapy. Int J Neurosci. 2002;112:119–131. doi: 10.1080/00207450212027.
    1. Shi XY, Tang ZQ, Sun D, He XJ. Evaluation of hyperbaric oxygen treatment of neuropsychiatric disorders following traumatic brain injury. Chin Med J (Engl) 2006;119:1978–1982.
    1. Golden Z, Golden CJ, Neubauer RA. Improving neuropsychological function after chronic brain injury with hyperbaric oxygen. Disabil Rehabil. 2006;28:1379–1386. doi: 10.1080/09638280600638364.
    1. Hardy P, Johnston KM, De Beaumont L, Montgomery DL, Lecomte JM, Soucy JP, Bourbonnais D, Lassonde M. Pilot case study of the therapeutic potential of hyperbaric oxygen therapy on chronic brain injury. J Neurol Sci. 2007;253:94–105. doi: 10.1016/j.jns.2006.12.005.
    1. Neubauer RA, James P. Cerebral oxygenation and the recoverable brain. Neurol Res. 1998;20:S33–36.
    1. Neubauer RA, Gottlieb SF, Miale A., Jr Identification of hypometabolic areas in the brain using brain imaging and hyperbaric oxygen. Clin Nucl Med. 1992;17:477–481. doi: 10.1097/00003072-199206000-00010.
    1. Stoller KP. Quantification of neurocognitive changes before, during, and after hyperbaric oxygen therapy in a case of fetal alcohol syndrome. Pediatrics. 2005;116:e586–591. doi: 10.1542/peds.2004-2851.
    1. Harch PG, Kriedt C, Van Meter KW, Sutherland RJ. Hyperbaric oxygen therapy improves spatial learning and memory in a rat model of chronic traumatic brain injury. Brain Res. 2007;1174:120–129. doi: 10.1016/j.brainres.2007.06.105.
    1. Montgomery D, Goldberg J, Amar M, Lacroix V, Lecomte J, Lambert J, Vanasse M, Marois P. Effects of hyperbaric oxygen therapy on children with spastic diplegic cerebral palsy: a pilot project. Undersea Hyperb Med. 1999;26:235–242.
    1. Collet JP, Vanasse M, Marois P, Amar M, Goldberg J, Lambert J, Lassonde M, Hardy P, Fortin J, Tremblay SD, Montgomery D, Lacroix J, Robinson A, Majnemer A. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. Lancet. 2001;357:582–586. doi: 10.1016/S0140-6736(00)04054-X.
    1. Sethi A, Mukherjee A. To see the efficacy of hyperbaric oxygen therapy in gross motor abilities of cerebral palsy children of 2–5 years, given initially as an adjunct to occupational therapy. The Indian Journal of Occupational Therapy. 2003;25:7–11.
    1. Waalkes P, Fitzpatrick DT, Stankus S, Topolski R. Adjunctive HBO treatment of children with cerebral anoxic injury. Army Medical Department Journal. 2002;April-June:13–21.
    1. Marois P, Vanasse M. Hyperbaric oxygen therapy and cerebral palsy. Dev Med Child Neurol. 2003;45:646–647. doi: 10.1017/S0012162203211191.
    1. Bennett M, Newton H. Hyperbaric oxygen therapy and cerebral palsy – where to now? Undersea Hyperb Med. 2007;34:69–74.
    1. Heuser G, Heuser SA, Rodelander D, Aguilera O, Uszler M. Treatment of neurologically impaired adults and children with "mild" hyperbaric oxygenation (1.3 ATM and 24% oxygen) In: Joiner JT, editor. Hyperbaric oxygenation for cerebral palsy and the brain-injured child. Flagstaff, Arizona: Best Publications; 2002.
    1. Ashamalla HL, Thom SR, Goldwein JW. Hyperbaric oxygen therapy for the treatment of radiation-induced sequelae in children. The University of Pennsylvania experience. Cancer. 1996;77:2407–2412. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2407::AID-CNCR33>;2-Z.
    1. Zilbovicius M, Boddaert N, Belin P, Poline JB, Remy P, Mangin JF, Thivard L, Barthelemy C, Samson Y. Temporal lobe dysfunction in childhood autism: a PET study. Positron emission tomography. Am J Psychiatry. 2000;157:1988–1993. doi: 10.1176/appi.ajp.157.12.1988.
    1. Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, Nishikawa M, Uema T, Sasaki M. Abnormal regional cerebral blood flow in childhood autism. Brain. 2000;123:1838–1844. doi: 10.1093/brain/123.9.1838.
    1. Boddaert N, Zilbovicius M. Functional neuroimaging and childhood autism. Pediatr Radiol. 2002;32:1–7. doi: 10.1007/s00247-001-0570-x.
    1. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81. doi: 10.1002/ana.20315.
    1. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005;17:485–495. doi: 10.1080/02646830500381930.
    1. Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum. 2005;4:206–210. doi: 10.1080/14734220500208846.
    1. Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch SB, Walker-Smith J, Thomson M, Wakefield AJ, O'Leary JJ. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol. 2002;55:84–90. doi: 10.1136/mp.55.2.84.
    1. Furlano RI, Anthony A, Day R, Brown A, McGarvey L, Thomson MA, Davies SE, Berelowitz M, Forbes A, Wakefield AJ, Walker-Smith JA, Murch SH. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138:366–372. doi: 10.1067/mpd.2001.111323.
    1. Sheffield PJ, Davis JC. Application of hyperbaric oxygen therapy in a case of prolonged cerebral hypoxia following rapid decompression. Aviat Space Environ Med. 1976;47:759–762.
    1. Vlodavsky E, Palzur E, Soustiel JF. Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury. Neuropathol Appl Neurobiol. 2006;32:40–50. doi: 10.1111/j.1365-2990.2005.00698.x.
    1. Sumen G, Cimsit M, Eroglu L. Hyperbaric oxygen treatment reduces carrageenan-induced acute inflammation in rats. Eur J Pharmacol. 2001;431:265–268. doi: 10.1016/S0014-2999(01)01446-7.
    1. Granowitz EV, Skulsky EJ, Benson RM, Wright J, Garb JL, Cohen ER, Smithline EC, Brown RB. Exposure to increased pressure or hyperbaric oxygen suppresses interferon-gamma secretion in whole blood cultures of healthy humans. Undersea Hyperb Med. 2002;29:216–225.
    1. Wilson HD, Wilson JR, Fuchs PN. Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain. Brain Res. 2006;1098:126–128. doi: 10.1016/j.brainres.2006.04.088.
    1. Takeshima F, Makiyama K, Doi T. Hyperbaric oxygen as adjunct therapy for Crohn's intractable enteric ulcer. Am J Gastroenterol. 1999;94:3374–3375. doi: 10.1111/j.1572-0241.1999.03374.x.
    1. Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol. 2001;33:337–339. doi: 10.1097/00004836-200110000-00018.
    1. Alleva R, Nasole E, Di Donato F, Borghi B, Neuzil J, Tomasetti M. alpha-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy. Biochem Biophys Res Commun. 2005;333:404–410. doi: 10.1016/j.bbrc.2005.05.119.
    1. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171–181.
    1. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611–1617.
    1. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141:947–956.
    1. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:341–343. doi: 10.1054/plef.2002.0439.
    1. Zoroglu SS, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, Meram I. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004;254:143–147.
    1. D'Amelio M, Ricci I, Sacco R, Liu X, D'Agruma L, Muscarella LA, Guarnieri V, Militerni R, Bravaccio C, Elia M, Schneider C, Melmed R, Trillo S, Pascucci T, Puglisi-Allegra S, Reichelt KL, Macciardi F, Holden JJ, Persico AM. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry. 2005;10:1006–1016. doi: 10.1038/sj.mp.4001714.
    1. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids. 2005;73:379–384. doi: 10.1016/j.plefa.2005.06.002.
    1. Yao Y, Walsh WJ, McGinnis WR, Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol. 2006;63:1161–1164. doi: 10.1001/archneur.63.8.1161.
    1. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin – the antioxidant proteins. Life Sci. 2004;75:2539–2549. doi: 10.1016/j.lfs.2004.04.038.
    1. Wada K, Miyazawa T, Nomura N, Tsuzuki N, Nawashiro H, Shima K. Preferential conditions for and possible mechanisms of induction of ischemic tolerance by repeated hyperbaric oxygenation in gerbil hippocampus. Neurosurgery. 2001;49:160–166. doi: 10.1097/00006123-200107000-00025.
    1. Yatsuzuka H. [Effects of hyperbaric oxygen therapy on ischemic brain injury in dogs] Masui. 1991;40:208–223.
    1. Ozden TA, Uzun H, Bohloli M, Toklu AS, Paksoy M, Simsek G, Durak H, Issever H, Ipek T. The effects of hyperbaric oxygen treatment on oxidant and antioxidants levels during liver regeneration in rats. Tohoku J Exp Med. 2004;203:253–265. doi: 10.1620/tjem.203.253.
    1. Yasar M, Yildiz S, Mas R, Dundar K, Yildirim A, Korkmaz A, Akay C, Kaymakcioglu N, Ozisik T, Sen D. The effect of hyperbaric oxygen treatment on oxidative stress in experimental acute necrotizing pancreatitis. Physiol Res. 2003;52:111–116.
    1. Kudchodkar BJ, Wilson J, Lacko A, Dory L. Hyperbaric oxygen reduces the progression and accelerates the regression of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1637–1643.
    1. Gregorevic P, Lynch GS, Williams DA. Hyperbaric oxygen modulates antioxidant enzyme activity in rat skeletal muscles. Eur J Appl Physiol. 2001;86:24–27. doi: 10.1007/s004210100503.
    1. Gulec B, Yasar M, Yildiz S, Oter S, Akay C, Deveci S, Sen D. Effect of hyperbaric oxygen on experimental acute distal colitis. Physiol Res. 2004;53:493–499.
    1. Nie H, Xiong L, Lao N, Chen S, Xu N, Zhu Z. Hyperbaric oxygen preconditioning induces tolerance against spinal cord ischemia by upregulation of antioxidant enzymes in rabbits. J Cereb Blood Flow Metab. 2006;26:666–674. doi: 10.1038/sj.jcbfm.9600221.
    1. Sharifi M, Fares W, Abdel-Karim I, Koch JM, Sopko J, Adler D. Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. Am J Cardiol. 2004;93:1533–1535. doi: 10.1016/j.amjcard.2004.03.009.
    1. Magalhaes J, Ascensao A, Viscor G, Soares J, Oliveira J, Marques F, Duarte J. Oxidative stress in humans during and after 4 hours of hypoxia at a simulated altitude of 5500 m. Aviat Space Environ Med. 2004;75:16–22.
    1. Fatemi SH, Halt AR, Stary JM, Realmuto GM, Jalali-Mousavi M. Reduction in anti-apoptotic protein Bcl-2 in autistic cerebellum. Neuroreport. 2001;12:929–933. doi: 10.1097/00001756-200104170-00013.
    1. Fatemi SH, Halt AR. Altered levels of Bcl2 and p53 proteins in parietal cortex reflect deranged apoptotic regulation in autism. Synapse. 2001;42:281–284. doi: 10.1002/syn.10002.
    1. Fatemi SH, Stary JM, Halt AR, Realmuto GR. Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum. J Autism Dev Disord. 2001;31:529–535. doi: 10.1023/A:1013234708757.
    1. Araghi-Niknam M, Fatemi SH. Levels of Bcl-2 and P53 are altered in superior frontal and cerebellar cortices of autistic subjects. Cell Mol Neurobiol. 2003;23:945–952. doi: 10.1023/B:CEMN.0000005322.27203.73.
    1. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, Jr, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 1994;14:6264–6277.
    1. Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996;56:2161–2166.
    1. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–491.
    1. Owley T, Walton L, Salt J, Guter SJ, Jr, Winnega M, Leventhal BL, Cook EH., Jr An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:343–348. doi: 10.1097/01.chi.0000153229.80215.a0.
    1. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, Research Units on Pediatric Psychopharmacology Autism Network Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–321. doi: 10.1056/NEJMoa013171.
    1. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord. 2003;33:427–433. doi: 10.1023/A:1025014929212.
    1. Edelson SM, Rimland B. Autism Treatment Evaluation Checklist (ATEC): Reliabilities and Score Distributions. 2000.
    1. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23:303–308.
    1. Jarusiewicz B. Efficacy of neurofeedback for children in the autism spectrum: a pilot study. J Neurotherapy. 2002;6:39–49. doi: 10.1300/J184v06n04_05.
    1. Shiratsuch H, Basson MD. Differential regulation of monocyte/macrophage cytokine production by pressure. Am J Surg. 2005;190:757–762. doi: 10.1016/j.amjsurg.2005.07.016.
    1. Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci. 2002;973:488–504.
    1. Patel V, Chivukula IV, Roy S, Khanna S, He G, Ojha N, Mehrotra A, Dias LM, Hunt TK, Sen CK. Oxygen: from the benefits of inducing VEGF expression to managing the risk of hyperbaric stress. Antioxid Redox Signal. 2005;7:1377–1387. doi: 10.1089/ars.2005.7.1377.
    1. Pablos MI, Reiter RJ, Chuang JI, Ortiz GG, Guerrero JM, Sewerynek E, Agapito MT, Melchiorri D, Lawrence R, Deneke SM. Acutely administered melatonin reduces oxidative damage in lung and brain induced by hyperbaric oxygen. J Appl Physiol. 1997;83:354–358.
    1. Yu SY, Chiu JH, Yang SD, Yu HY, Hsieh CC, Chen PJ, Lui WY, Wu CW. Preconditioned hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in rats. J Surg Res. 2005;128:28–36.
    1. Pelaia P, Rocco M, De Blasi RA, Spadetta G, Alampi D, Araimo FS, Nicolucci S. [Assessment of lipid peroxidation in hyperbaric oxygen therapy: protective role of N-acetylcysteine] Minerva Anestesiol. 1995;61:133–139.
    1. Hollis AL, Butcher WI, Davis H, Henderson RA, Stone WL. Structural alterations in retinal tissues from rats deficient in vitamin E and selenium and treated with hyperbaric oxygen. Exp Eye Res. 1992;54:671–684. doi: 10.1016/0014-4835(92)90022-K.
    1. Boadi WY, Thaire L, Kerem D, Yannai S. Effects of dietary factors on antioxidant enzymes in rats exposed to hyperbaric oxygen. Vet Hum Toxicol. 1991;33:105–109.
    1. Weber CA, Duncan CA, Lyons MJ, Jenkinson SG. Depletion of tissue glutathione with diethyl maleate enhances hyperbaric oxygen toxicity. Am J Physiol. 1990;258:L308–312.
    1. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765–774. doi: 10.1016/0278-5846(93)90058-Z.
    1. Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002;17:833–837.
    1. Al-Waili NS, Butler GJ. Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action. ScientificWorldJournal. 2006;6:425–441. doi: 10.1100/tsw.2006.78.
    1. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168.
    1. Starkstein SE, Vazquez S, Vrancic D, Nanclares V, Manes F, Piven J, Plebst C. SPECT findings in mentally retarded autistic individuals. J Neuropsychiatry Clin Neurosci. 2000;12:370–375.
    1. Wilcox J, Tsuang MT, Ledger E, Algeo J, Schnurr T. Brain perfusion in autism varies with age. Neuropsychobiology. 2002;46:13–16. doi: 10.1159/000063570.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi